Last update 20 Mar 2025

Teicoplanin

Overview

Basic Info

Drug Type
Synthetic peptide
Synonyms
TEIC, Teichomycin, Teichomycin A2
+ [12]
Target-
Action
inhibitors
Mechanism
Cell wall inhibitors
Inactive Indication
Originator Organization
Drug Highest PhaseApproved
First Approval Date
Japan (10 Apr 1998),
RegulationOrphan Drug (European Union)
Login to view timeline

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Empyema
Japan
10 Apr 1998
Hemorrhagic Septicemia
Japan
10 Apr 1998
Pneumonia
Japan
10 Apr 1998
Skin and skin structure infections
Japan
10 Apr 1998
Skin Diseases
Japan
10 Apr 1998
Gram-Positive Bacterial Infections
China
-
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Cystic FibrosisPhase 1
Italy
25 Oct 2019
Cystic FibrosisPhase 1
Italy
25 Oct 2019
Hemorrhagic Fever, EbolaPreclinical
China
01 Apr 2016
Severe Acute Respiratory SyndromePreclinical
China
01 Apr 2016
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
vzqkadtruv(ubtwdualrd) = kvytbcizgp epnfmtowqw (rmzqmtzpdu, 0.3)
Positive
01 Feb 2014
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free